About the Company
The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Oncology Institute, Inc.
The Oncology Institute, Inc. (NASDAQ:TOI) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 The Oncology Institute, Inc. misses on earnings expectations. Reported EPS ...
The Oncology Institute Inc (TOI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
The Oncology Institute Inc (TOI) reports over 20% revenue growth and significant contract expansions, while navigating EBITDA ...
Oncology Institute Shares Drop 7% as Earnings Miss Despite Revenue Growth
The Oncology Institute, Inc. (NASDAQ:TOI) saw its shares fall 7.07% in pre-market trading Thursday after reporting ...
The Oncology Institute, Inc. to Release Q2 2025 Financial ... - Nasdaq
The Oncology Institute, Inc. (TOI) announced that it will release its financial results for the second quarter of 2025 on August 13, 2025, after market close, followed by a conference call at 5:00 ...
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript Nov. 13, 2024 7:25 PM ET The Oncology Institute, Inc. (TOI) Stock, TOIIW Stock TOI, TOIIW SA Transcripts 154.93K Follower s ...
The Oncology Institute, Inc. Scheduled to Release Q4 and Full ... - Nasdaq
The Oncology Institute, Inc. (TOI), a leading value-based oncology group in the U.S., announced it will release its financial results for the fourth quarter and full year 2024 on March 25, 2025 ...
The Oncology Institute, Inc. (NASDAQ:TOI) Q4 2023 Earnings Call ...
The Oncology Institute, Inc. misses on earnings expectations. Reported EPS is $-0.21 EPS, expectations were $-0.11.
The Oncology Institute Announces Changes to Board of Directors
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New ChairmanCERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: ...
The Oncology Institute shares tumble 7% as earnings miss overshadows revenue beat
The value-based community oncology group reported a second quarter loss of $0.15 per share, missing analyst estimates of a $0.09 loss by $0.06. Revenue came in at $119.8 million, surpassing the ...
Why The Oncology Institute, Inc. (TOI) is Surging in 2025
The Oncology Institute, Inc. (NASDAQ:TOI) stock is up 971.20% year-to-date. Overall, TOI ranks 1st on our list of healthcare stocks that are surging in 2025.
The Oncology Institute Announces Second Quarter 2025 Earnings Release ...
CERRITOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced ...
The Oncology Institute, Inc. (TOI) Q1 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ: TOI) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer ...
Similar Companies
| Company | Ticker | 90 Days Forecast | Market Cap. (USD M) | P/E | P/B |
|---|---|---|---|---|---|
| Airsculpt Technologies, Inc. | AIRS | Predict | 390.54 | -68.82 | 4.28 |
| Hims & Hers Health, Inc. | HIMS | Predict | 945.54 | -14.34 | 2.89 |
| LifeMD, Inc. | LFMD | Predict | -62.12 | 0.00 | -205.89 |
| LifeMD, Inc. | LFMDP | Predict | -231.87 | 0.00 | -456.68 |
| SBC Medical Group Holdings Inc | SBC | Predict | 568.83 | None | 2.51 |
| SBC Medical Group Holdings Inc | SBCWW | Predict | 26.79 | None | 0.13 |
| Teladoc Health, Inc. | TDOC | Predict | 1328.09 | -1.77 | 0.93 |
| Oncology Institute, Inc. | TOI | Predict | 313.03 | -0.28 | 61.75 |
| Oncology Institute, Inc. | TOIIW | Predict | 2.27 | None | 0.15 |
Loading the latest forecasts...